# Tubulis funding rounds and investors

As of 14 Oct 2026, Tubulis has raised $358.0M across 1 verified round on record (amounts in other currencies converted to USD); latest: €308 million (USD 361 million) Series C led by Venrock Healthcare Capital Partners, announced 15 Oct 2025.

Tubulis develops antibody-drug conjugates for treating various cancers.

Website: https://tubulis.com  
Page: https://fireround.dev/companies/tubulis.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-10-15 | Series C | €308 million (USD 361 million) | Venrock Healthcare Capital Partners | Andera Partners, Ascenta Capital, Bayern Kapital, Deep Track Capital, EQT Life Sciences, Frazier Life Sciences, Fund+, High-Tech Gründerfonds (HTGF), Nextech Invest, OCCIDENT, Seventure Partners, Wellington Management | [businesswire.com](https://www.businesswire.com/news/home/20251015424129/en/Tubulis-Raises-%E2%82%AC308-Million-Series-C-to-Accelerate-Clinical-Development-of-Lead-ADC-Candidate-TUB-040-and-Expand-Pipeline) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.